



Swiss Group for Clinical Cancer Research (SAKK)

Contact

Swiss Group for Clinical Cancer Research (SAKK)

Publications (33)

Mark M, Froesch P, Gysel K, Rothschild S, Addeo A, Ackermann C, Chiquet S, Schneider M, Ribi K, Maranta A, Bastian S, von Moos R, Jörger M, Früh M, Swiss Group for Clinical Cancer Research (SAKK). First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. *Eur J Cancer* 2024; 200:113600.

Hilberink J, van Zeventer I, Chitu D, Pabst T, Klein S, Stussi G, Griskevicius L, Valk P, Cloos J, van de Loosdrecht A, Breems D, van Lammeren-Venema D, Boersma R, Jongen-Lavrencic M, Fehr M, Hoogendoorn M, Manz M, Söhne M, van Marwijk Kooy R, Deeren D, van der Poel M, Legdeur M, Tick L, Chalandon Y, Ammatuna E, Blum S, Löwenberg B, Ossenkoppele G, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), Swiss Group for Clinical Cancer Research (SAKK), Huls G. Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine. *Blood Cancer J* 2023; 13:93.

Jörger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt A, Cantoni N, Caspar C, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz J, Kopp C, Hayoz S, Stathis A, von Moos R, Swiss Group for Clinical Cancer Research (SAKK). Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). *Cancers (Basel)* 2022; 14

Rothschild S, Cathomas R, Ochsenbein A, Janthur W, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Godar G, Rusterholz C, Gonzalez M, Pless M, Mark M, Peters S, Zippelius A, Eboulet E, Savic Prince S, Betticher D, Bettini A, Früh M, Jörger M, Lardinois D, Gelpke H, Mauti L, Britschgi C, Weder W, Swiss Group for Clinical Cancer Research (SAKK). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. *J Clin Oncol* 2021; 39:2872-2880.

Ghadjar P, Zaugg K, Guckenberger M, Ost P, Reuter C, Bosetti D, Kaouthar K, Gomez S, Wust P, Thalmann G, Aebersold D, Sumila M, Schär C, Hayoz S, Bernhard J, Zwahlen D, Hölscher T, Gut P, Polat B, Hildebrandt G, Müller A, Plasswilm L, Papachristofilou A, Swiss Group for Clinical Cancer Research (SAKK). Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09/10 Randomized Phase 3 Trial. *Eur Urol* 2021; 80:306-315.

Froesch P, Früh M, Gautschi O, Sessa C, König D, Metaxas Y, Colombo I, Schmid S, Oppliger Leibundgut E, Rusterholz C, Godar G, Li Q, Rothschild S, Mark M, Swiss Group for Clinical Cancer Research (SAKK). Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial. *Lung Cancer* 2021; 156:91-99.

Barbier M, Pardo E, Panje C, Gautschi O, Lupatsch J, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerland. *Eur J Health Econ* 2021; 22:669-677.

Mark M, Früh M, Biaggi-Rudolf C, Weindler S, Baudoux N, Schwitler M, Wannesson L, Jörger M, Metaxas Y, Schneider M, Friedlaender A, Burmeister H, Janthur W, Rothschild S, Pless M, Addeo A, Eboulet E, Froesch P, Swiss Group for Clinical Cancer Research (SAKK). SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2. *Cancer Immunol Immunother* 2020

Panje C, Schwenkglens M, Gautschi O, Plasswilm L, Aebersold D, Dedes K, Lorez M, Pardo E, Barbier M, Lupatsch J, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. *Ann Oncol* 2020; 31:501-506.

Metaxas Y, von Moos R, Rauch D, Appenzeller C, Waibel C, Schmid S, Froesch P, Biaggi-Rudolf C, Perrino M, Maconi A, Schneider M, Mark M, Ceresoli G, Zucali P, Pless M, Grosso F, Eboulet E, Früh M, Swiss Group for Clinical Cancer Research (SAKK). Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16). *Ann Oncol* 2020; 31:495-500.

Panje C, Plasswilm L, Ruhstaller T, Gerard M, Hawle H, Schacher S, Henke G, Meier U, Garcia Schüler H, Herrmann E, Baracos V, Hayoz S, Höng L, Swiss Group for Clinical Cancer Research (SAKK). Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. *Radiat Oncol* 2019; 14:166.

Riesterer O, Krayenbuehl J, Weder W, Sabrina Stark L, Zimmermann F, Nackaerts K, Zwahlen D, Mahmut Ozsahin E, Plasswilm L, Aebersold D, Xyrafas A, Stahel R, Ciernik I, Swiss Group for Clinical Cancer Research (SAKK). Pattern of failure after adjuvant radiotherapy following extrapleural pneumonectomy of pleural mesothelioma in the SAKK 17/04 trial. *Radiother Oncol* 2019; 138:121-125.

Panje C, Lupatsch J, Plasswilm L, Aebersold D, Siano M, Gautschi O, Schwenkglens M, Matter-Walstra K, Dedes K, Swiss Group for Clinical Cancer Research (SAKK). A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). *Radiother Oncol* 2018; 129:257-263.

Weber W, Sarlos D, Leo C, Canonica C, Gabriel N, Zeindler J, Cassoly E, Andrieu C, Soysal S, Ruhstaller T, Fehr P, Knauer M, Pioch V, Güth U, Hess T, Tausch C, Hayoz S, Fehr M, Ribi K, Hawle H, Lupatsch J, Matter-Walstra K, Chiesa F, Dedes K, Berclaz G, Lelièvre L, Swiss Group for Clinical Cancer Research (SAKK). Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial. *Ann Surg Oncol* 2018; 25:2632-2640.

von Moos R, Plasswilm L, Zwahlen D, Meier U, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K, Saletti P, Rauch D, Koeberle D, Schacher S, Hayoz S, Winterhalder R, Roth A, Bodoky G, Samaras P, Berger M, Swiss Group for Clinical Cancer Research (SAKK). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). *Eur J Cancer* 2017; 89:82-89.

Ghadjar P, Thalmann G, Aebersold D, Wust P, Biaggi Rudolf C, Dal Pra A, Schär C, Papachristofilou A, Putora P, Müller A, Hildebrandt G, Polat B, Gut P, Hölscher T, Stein J, Zwahlen D, Bernhard J, Hayoz S, Swiss Group for Clinical Cancer Research (SAKK). Impact of dose intensified salvage radiation therapy on urinary continence recovery after radical prostatectomy: Results of the randomized trial SAKK 09/10. *Radiother Oncol* 2017

Steffen T, Ruhstaller T, Brauchli P, Thierstein S, Schiesser M, Gloor B, Furrer M, Marti W, Huber O, Kettelhack C, Schnider A, Dietrich D, Swiss Group for Clinical Cancer Research (SAKK). Recurrence Patterns and Long-term Results After Induction Chemotherapy, Chemoradiotherapy, and Curative Surgery in Patients With Locally Advanced Esophageal Cancer. *Ann Surg* 2017; 269:83-87.

Stathis A, Sessa C, Gargiulo P, Berardi S, Enou M, Xyrafas A, Catapano C, Allegrini S, Ackermann C, Mark M, Jörger M, Griguolo G, Homicsko K, von Moos R, Hess D, Swiss Group for Clinical Cancer Research (SAKK). Phase I trial of the oral smoothed inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors. *Invest New Drugs* 2017; 35:766-772.

Ghadjar P, Kranzbühler H, Najafi Y, Ost P, Azinwi N, Reuter C, Bodis S, Kaouthar K, Budach V, Aebersold D, Thalmann G, Sumila M, Biaggi-Rudolf C, Stalder L, Hayoz S, Genitsch V, Zwahlen D, Hölscher T, Gut P, Guckenberger M, Hildebrandt G, Müller A, Putora P, Papachristofilou A, Swiss Group for Clinical Cancer Research (SAKK). Importance and outcome relevance of central pathology review in prostatectomy specimens: data from the SAKK 09/10 randomized trial on prostate cancer. *BJU Int* 2017; 120:E45-E51.

Strasser F, Koeberle D, Kaasa S, Mauri S, Haefner M, Brauchli P, Klingbiel D, Hayoz S, Betticher D, Aebi S, Ribi K, Cathomas R, von Moos R, Blum D, Swiss Group for Clinical Cancer Research (SAKK). The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06). *Ann Oncol* 2015

Rordorf T, Hassan A, Azim H, Alexandru E, Er O, Gokmen E, Güral Z, Mardiak J, Minchev V, Peintinger F, Szendroi M, Takac I, Tesarova P, Vorobiof D, Vrbancic D, Yildiz R, Yücel S, Zekri J, Oyan B, Swiss Group for Clinical Cancer Research (SAKK). Bone health in breast cancer patients: a comprehensive statement by CECOG/SAKK Intergroup. *Breast* 2014; 23:511-25.

Templeton A, Schiess R, Wild P, Rüschoff J, Thalmann G, Dietrich P, Aebbersold R, Klingbiel D, Gillessen Sommer S, Müller B, Winterhalder R, Stenner F, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Swiss Group for Clinical Cancer Research (SAKK). Phase 2 trial of single-agent everolimus in chemotherapy-naïve patients with castration-resistant prostate cancer (SAKK 08/08). *Eur Urol* 2013; 64:150-8.

Schoenewolf N, von Moos R, Schraml P, Gillessen Sommer S, Ochsenbein A, Simcock M, Moch H, Mihic-Probst D, Dummer R, Swiss Group for Clinical Cancer Research (SAKK). Detecting BRAF Mutations in Formalin-Fixed Melanoma: Experiences with Two State-of-the-Art Techniques. *Case Rep Oncol* 2012; 5:280-9.

Köberle D, Thürlimann B, Pilop C, Crowe S, Öhlschlegel C, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). *Endocr Relat Cancer* 2011; 18:257-64.

Rochlitz C, Zaman K, Mayer M, Cliffe B, Herrmann R, Mannhart-Harms M, Müller A, Rauch D, Winterhalder R, von Moos R, Schonenberger A, Fehr M, Bühlmann M, Suter T, Huober J, Spirig C, Lerch S, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). *Ann Oncol* 2010; 22:80-5.

Ruhstaller T, Popescu R, Bodis S, Schnider A, Terraciano L, Köberle D, Balmermajno S, Pestalozzi B, Borner M, von Moos R, Mingrone W, Hess V, Roth A, Schuller J, Widmer L, Swiss Group for Clinical Cancer Research (SAKK). Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75/02). *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2009; 20:1522-8.

Zenhäusern R, Tobler A, Leoncini L, Kovacovic T, Bargetzi M, Hess U, Gratwohl A, Meyer-Monard S, Solenthaler M, Rufibach K, von Rohr A, Swiss Group for Clinical Cancer Research (SAKK). Low dose 2-chlorodeoxyadenosine given as a single subcutaneous injection in patients with hairy cell leukemia: a multicentre trial SAKK 32/95. *Leukemia & lymphoma* 2009; 50:133-6.

Leyvraz S, Pestalozzi B, Dietrich D, Cerny T, Wernli M, Sessa C, Fey M, Christinat A, Honegger H, Guillou L, Herrmann R, Swiss Group for Clinical Cancer Research (SAKK). Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. *British journal of cancer* 2006; 95:1342-7.

Cogliatti S, Novak U, Henz S, Schmid U, Möller P, Barth T, Swiss Group for Clinical Cancer Research (SAKK). Diagnosis of Burkitt lymphoma in due time: a practical approach. *British journal of haematology* 2006; 134:294-301.

Betticher D, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Ris H, Stahel R, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Swiss Group for Clinical Cancer Research (SAKK). Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. *British journal of cancer* 2006; 94:1099-106.

Sabbioni M, Hürny C, Goldhirsch A, Herrmann R, Perey L, Bonnefoi H, Thürlimann B, Gertsch M, Schmitz S, Siegrist H, Bernhard J, Swiss Group for Clinical Cancer Research (SAKK). Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?. *Breast Cancer Res Treat* 2004; 87:75-86.

Köberle D, Perey L, Thürlimann B, Swiss Group for Clinical Cancer Research (SAKK). Re: Playing the old piano: another tune for endocrine therapy. *Journal of the National Cancer Institute* 2004; 96:555-6; author reply 556-7.

Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann B, Goldhirsch A, Brunner K, Borner M, Swiss Group for Clinical Cancer Research (SAKK). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. *Annals of oncology : official journal of the European Society for Medical Oncology / ESMO* 2003; 14:1215-21.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch